Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CH0100191136
Wed, 18.09.2024
Relief Therapeutics Holding SA
Relief Therapeutics Holding SA
/ Key word(s): Study
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024
18.09.2024 / 07:00 CET/CEST
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October [ … ]
Wed, 18.09.2024
Relief Therapeutics Holding SA
Relief Therapeutics Holding SA
/ Key word(s): Study
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024
18.09.2024 / 07:00 CET/CEST
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October [ … ]
Mon, 02.09.2024
Relief Therapeutics Holding SA
Relief Therapeutics Holding SA
/ Key word(s): Study
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
02.09.2024 / 07:00 CET/CEST
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
GENEVA (SEPT. 2, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RL [ … ]
Fri, 30.08.2024
Relief Therapeutics Holding SA
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
RLF-TD011 investigator-initiated trial results for EB wound treatment anticipated in the coming weeks
RLF-OD032 pilot PK study progresses with potential NDA filing by mid- to late 2025
Streamlined operations and CHF 15.1 million cash reserves expected to p [ … ]
Mon, 05.08.2024
Relief Therapeutics Holding SA
Relief Therapeutics Secures up to $11 Million from Royalty SalesNon-dilutive funding to support RLF-TD011 clinical development and pipeline advancement
GENEVA (Aug. 5, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for [ … ]
Thu, 27.06.2024
Relief Therapeutics Holding SA
.awlist1_1719466159_233481 { list-style:none; counter-set:awlistcounter1 }
.awlist1_1719466159_233481 li:before { content:'5.' counter(awlistcounter1); counter-increment:awlistcounter1 }
.awlist2_1719466159_233481 { list-style:none; counter-set:awlistcounter2 1 }
.awlist2_1719466159_233481 li:before { content:'5.' counter(awlistcounter2); [ … ]
Mon, 03.06.2024
Relief Therapeutics Holding SA
Relief Therapeutics Announces Executive Changes
GENEVA (June 3, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that interim Chief Executive [ … ]
Mon, 03.06.2024
Relief Therapeutics Holding SA
Relief Therapeutics Announces Executive Changes
GENEVA (June 3, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that interim Chief Executive [ … ]
Thu, 30.05.2024
Relief Therapeutics Holding SA
Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders
GENEVA (MAY 30, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the Annual General Meeting (AGM) o [ … ]
Wed, 08.05.2024
Relief Therapeutics Holding SA
Relief Therapeutics Announces New Executive Leadership Team strengthening capabilities to guide the Company through pipeline development initiatives
GENEVA (MAY 8, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for sel [ … ]